Bain Capital is in talks to acquire Mitsubishi Chemical Group’s pharmaceutical business in a potential multibillion-dollar ...

Japan's Mitsubishi Chemical Group has picked U.S. investment fund Bain Capital as the preferred bidder for its pharmaceutical ...

Investment firm Bain Capital is in talks to acquire Mitsubishi Tanabe Pharma Corp., affiliated to Japan's Mitsubishi Chemical Group ...

Mitsubishi Chemical Group is stepping up its efforts to streamline operations by entering negotiations with U.S. investment ...

Synaffix B.V. ("Synaffix"), a Lonza company (SWX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class ...

March 2024: Moleac Pte Ltd announced a study of Phase 4 clinical trials for NeuroAiD. SATURN investigates the promising role ...

(RTTNews) - Investment firm Bain Capital is in talks to acquire Mitsubishi Tanabe Pharma Corp., affiliated to Japan's Mitsubishi Chemical Group (MTLHF.PK), in a potential deal, reports said citing ...

Nikkei reported on Monday the company is likely to sell its Tanabe Mitsubishi Pharma unit to Bain Capital for more than 500 billion yen ($3.2 billion). Mitsubishi Chemical said in a statement on ...

AMSTERDAM, Jan. 9, 2025 /PRNewswire/ -- Synaffix B.V. ("Synaffix"), a Lonza company (SWX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody ...

Tanabe Mitsubishi Pharma, in a deal that could value it at over $3 billion, two people with knowledge of the situation said. The two sides are in final negotiations, said one of the people ...